Scholarlink

Background <p>High-grade squamous intraepithelial lesions (HSIL) of the anal region are recognized as precursor lesions to squamous cell carcinoma of the anus (SCCA), especially in individuals infected with the human papillomavirus (HPV). Although recent studies indicate that treating HSIL can reduce progression to SCCA, optimal management strategies remain undefined. High recurrence rates and treatment-associated morbidities underscore the need for effective therapeutic options.</p> Methods <p>A&#xa0;survey among radiation oncologists in Germany was conducted between September and October 2024, covering clinical practice settings, the frequency of HSIL cases, experience with radiotherapy, reasons for radiotherapy inquiries, treatment indications, and concurrent therapies.</p> Results <p>A&#xa0;total of 58&#xa0;radiation oncologists participated in the survey, with 37&#xa0;(63.8%) reporting inquiries about radiotherapy for HSIL, primarily for patients with multiple recurrences. Radiotherapy was generally considered an appropriate option, particularly for recurrent cases where other treatments posed risks, especially complications or worsening of anorectal function after local excision. However, only half of the respondents&#xa0;(29) had prior experience with treating anal HSIL and rated radiotherapy outcomes as good or very good. Most respondents indicated a&#xa0;preference for treating only the local area (i.e., excluding lymphatic drainage pathways) to a&#xa0;total dose of 40–50 Gy.</p> Conclusion <p>Recurrent anal HSIL presents a&#xa0;major challenge for patients, with no established effective treatment standards available. Radiotherapy is frequently requested and administered, showing promising preliminary outcomes. Clinical studies are warranted to evaluate the effectiveness and tolerability of radiotherapy in patients with anal HSIL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiation therapy in anal high-grade squamous intraepithelial lesions—a pattern of care analysis in German-speaking countries

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月7日

查看全文
  • Hendrik Dapper,
  • Claudia Rudroff,
  • Philipp Linde,
  • Johannes Rosenbrock,
  • Joel Schmitz,
  • Simone Ferdinandus,
  • Karolina Jablonska,
  • Daniel Martin,
  • Claus Rödel,
  • Emmanouil Fokas

摘要

Background

High-grade squamous intraepithelial lesions (HSIL) of the anal region are recognized as precursor lesions to squamous cell carcinoma of the anus (SCCA), especially in individuals infected with the human papillomavirus (HPV). Although recent studies indicate that treating HSIL can reduce progression to SCCA, optimal management strategies remain undefined. High recurrence rates and treatment-associated morbidities underscore the need for effective therapeutic options.

Methods

A survey among radiation oncologists in Germany was conducted between September and October 2024, covering clinical practice settings, the frequency of HSIL cases, experience with radiotherapy, reasons for radiotherapy inquiries, treatment indications, and concurrent therapies.

Results

A total of 58 radiation oncologists participated in the survey, with 37 (63.8%) reporting inquiries about radiotherapy for HSIL, primarily for patients with multiple recurrences. Radiotherapy was generally considered an appropriate option, particularly for recurrent cases where other treatments posed risks, especially complications or worsening of anorectal function after local excision. However, only half of the respondents (29) had prior experience with treating anal HSIL and rated radiotherapy outcomes as good or very good. Most respondents indicated a preference for treating only the local area (i.e., excluding lymphatic drainage pathways) to a total dose of 40–50 Gy.

Conclusion

Recurrent anal HSIL presents a major challenge for patients, with no established effective treatment standards available. Radiotherapy is frequently requested and administered, showing promising preliminary outcomes. Clinical studies are warranted to evaluate the effectiveness and tolerability of radiotherapy in patients with anal HSIL.